This article was originally published in Start Up
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
You may also be interested in...
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.
These days, consumers reach for calcium-fortified orange juice to keep bones healthy, whole-grain Cheerios that reduce the risk of heart disease and cancer, and bags of walnuts that advertise Omega 3, for heart health. The founders of WellGen believe the time is right to push the frontier of food science into medicine. With a patent from Rutgers University, WellGen will screen food substances against genes implicated in diseases.
AlphaGenics is launching a consumer-focused nutrigenomics business. It will track its client's diets and compare their food intake to changes in their gene expression, over time building a database that the company believes will become a valuable research tool for advancing the emerging science of nutrigenomics.